UNIVERSITY OF KWAZULU-NATAL

Gilead Sciences has initiated the first known HIV cure trial in South Africa, specifically targeting women who are significantly underrepresented in HIV clinical research despite bearing a disproportionate disease burden.

A groundbreaking Phase IIa clinical trial in South Africa has demonstrated that a combination of broadly neutralizing antibodies and immune stimulants may enable some HIV patients to control the virus without daily antiretroviral therapy.